Research.Patient.info

CD123 positive R/R AML and intermediate risk, high risk, or extremely high risk MDS. research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
Phase 1 trial of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2-T cell engager, in patients with CD123 positive relapsed/refractory (R/R) acute myeloid leukemia (AML) and intermediate risk, high risk, or extremely high-risk myelodysplastic syndrome (MDS)
This early study is testing a new drug, LAVA-1266, for people over 18 with certain types of acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) that have come back or not responded to previous treatments. It aims to see if the drug is safe and what dose works best.
Spain